A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes

A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or without adequate control on metformin will be sufficiently safe and well tolerated to permit continued clinical investigation.

Inclusion Criteria:

• Nonsmoking Male or Female (of non-child bearing potential)
• Diagnosis of Type 2 Diabetes and is being treated with diet and exercise alone or with less than 3 oral anti-hyperglycemic agents
• Panel E only (MK0941 60 mg before 2 meals each day): diagnosis of Type 2 Diabetes and is on a dose of metformin of greater than or equal to 1500 mg for 8 weeks or more

Exclusion Criteria:

• Subject is on insulin or a peroxisome proliferator-activated receptor (PPAR) agonist
• Subject is on 3 or more oral anti-diabetes medications
• Subject has a history of type 1 diabetes
• Subject has a diagnosis of glaucoma or is blind
• Subject has had trauma to one or both eyes